ArticleOncotarget2017
Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis.BMC gastroenterology · 2023Pooled it
- A serum Golgi Protein 73 (GP73)-based model for evaluating inflammation associated with drug-induced liver injury.Clinics (Sao Paulo, Brazil) · 2026Article
- Golgi Protein 73 and Laminin-γ2 Monomer-Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
- [Role of serum Golgi protein 73 in the assessment of pathological prognosis and its inflammatory influencing factors for hepatitis B virus-related liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Golgi protein 73 and IL-6 as strong predictors of short-term prognosis in patients with HBV-ACLF.Scientific reports · 2025Article
- Development and analytical performance of a new research use only (RUO) GP73 automated immunoassay.Biochemistry and biophysics reports · 2025Article
- Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure.Immunity, inflammation and disease · 2025Article
- [The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF.Journal of clinical and translational hepatology · 2022Article
- [Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.Disease markers · 2022Article
- Article
- Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis.Medical journal, Armed Forces India · 2021Article
- Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease.Biomolecules · 2021Article
- Golgi Phosphoprotein 73: The Driver of Epithelial-Mesenchymal Transition in Cancer.Frontiers in oncology · 2021Review
- Golgi protein 73, hepatocellular carcinoma and other types of cancers.Liver research (Beijing, China) · 2020Article
- Combination of biomarkers for the detection of hepatocellular carcinoma.Annals of translational medicine · 2020Article
- Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.World journal of gastroenterology · 2020Article
- Recent advances of GOLM1 in hepatocellular carcinoma.Hepatic oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the present study, we found that the serum GP73 increased in HCC patients with cirrhosis but not in those without cirrhosis. The receiver operating characteristic curve (ROC) analysis demonstrated that serum GP73 had poor performance for differentiating HCC patients from cirrhosis patients. In addition, the immunohistochemistry revealed that aberrant expression of GP73 was primarily observed in cirrhotic and tumor liver tissues from both cirrhosis and HCC patients, but rarely in non-cirrhotic liver tissues from HCC patients without cirrhosis. Moreover, serum Alpha-fetoprotein in HCC patients with cirrhosis decreased sharply after resection of tumor tissue, while the serum GP73 remained stable. These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients. In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.